Bold Therapeutics
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
515-850 W Hastings St, Vancouver, Britis...Phone Number
(604) 262-9899Website
www.bold-therapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Bold Therapeutics
Bold Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel metallotherapeutics aimed at advanced cancer treatment. The company focuses on addressing unmet needs in oncology by leveraging the clinical benefits of metal-based therapeutics, with its lead candidate BOLD-100 showing promise in treating various gastrointestinal cancers. Bold Therapeutics is advancing its clinical trials, including a Phase 3 trial in metastatic colorectal cancer and a Phase 2/3 trial in bile duct cancer, while also pursuing designations for breakthrough therapy in gastrointestinal indications. With a veteran team and versatile technology, Bold Therapeutics aims to enhance the effectiveness of existing cancer therapies and improve patient outcomes.Explore more
Bold Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Bold Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Bold Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Bold Therapeutics
Earning: See what the market has to say on Bold Therapeutics recently announced quarterly report
Product Launch: Get notified when Bold Therapeutics launches new products
Bold Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Bold Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Bold Therapeutics has new funding data
Check out if Bold Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Bold Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Bold Therapeutics
Compare insights from companies similar to Bold Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Bold Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Bold Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Bold Therapeutics.
Bold Therapeutics Tech Stack
A closer look at the technologies used by Bold Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Person-Based
Bold Therapeutics News & Media
Bold Therapeutics' Clinical-Stage Anticancer Agent BOLD-100 Demonstrates Neuroprotective Potential when Utilized in Combination with FOLFOX for the Treatment of Advanced Gastrointestinal Cancers
VANCOUVER, BC, May 28, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company founded to develop and commercialize novel metallotherapeutics, is presenting data to support the neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for...Bold Therapeutics' Clinical-Stage Anticancer Agent BOLD-100 Demonstrates Protective Effects Against Chemotherapy-Induced Peripheral Neuropathy
VANCOUVER, BC, April 16, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company that was founded to develop and commercialize novel metallotherapeutics, has shared new data highlighting the ability of its lead asset, BOLD-100, to demonstrate protective effects...Bold Therapeutics Attending BIO-Europe Spring 2026 in Lisbon, Portugal
VANCOUVER, BC, March 20, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company that was founded to develop and commercialize novel metallotherapeutics, announces that they are attending BIO-Europe Spring 2026 in Lisbon, Portugal next week from March 23-25....Bold Therapeutics Presents Late-Breaking Poster on BOLD-100's Unique Ability to Mitigate Oxaliplatin-Induced Peripheral Neuropathy (OIPN) at AACR Annual Meeting 2025
VANCOUVER, BC, April 30, 2025 /PRNewswire/ -- Bold Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering novel oncology treatments, today announced that its Sr. Director of Preclinical Development, Mark Bazett, PhD, is presenting a late-breaking poster on BOLD-100's...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Bold Therapeutics
Sign Up For FreeTo access detailed company insights
Bold Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel metallotherapeutics aimed at advanced cancer treatment. The company focuses on addressing unmet needs in oncology by leveraging the clinical benefits of metal-based therapeutics, with its lead candidate BOLD-100 showing promise in treating vario... Read More
